That tactic, called "product hopping," is a strategy drug makers have begun using in recent years to stall the development of generic versions of a medication so they can keep brand-name drug prices high. But it is coming under fire from the Federal Trade Commission and several consumer groups, which charge in a federal court case that it’s a violation of antitrust law that bilks consumers of millions of dollars in high drug prices.
Read Full Article »
